Join to View Full Profile
333 Cottman AvePhiladelphia, PA 19111
Phone+1 215-728-2500
Fax+1 215-728-3639
Are you Dr. Lubiniecki?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Gregory Lubiniecki, MD is an oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, New Jersey, and Minnesota.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2001 - 2004
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1998 - 2001
Johns Hopkins University School of MedicineClass of 1998
Certifications & Licensure
PA State Medical License 2001 - 2026
NJ State Medical License 2004 - 2009
MN State Medical License 1999 - 2001
Publications & Presentations
PubMed
- 31 citationsLenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.Robert J Motzer, Matthew H Taylor, Thomas R Jeffry Evans, Takuji Okusaka, Hilary Glen
Expert Review of Anticancer Therapy. 2022-04-01 - 41 citationsThe LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors.Matthew H. Taylor, Emmett V. Schmidt, Corina E. Dutcus, Elaine M. Pinheiro, Yasuhiro Funahashi
Future Oncology. 2021-02-01 - 177 citationsLong-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 S...Roy S. Herbst, Edward B. Garon, Dong Wan Kim, Byoung Chul Cho, Jose Luis Perez-Gracia
Journal of Clinical Oncology. 2020-02-20
Press Mentions
Merck Begins Trial Evaluating Zilovertamab Vedotin for Previously Untreated Diffuse Large B-cell LymphomaFebruary 8th, 2025- Merck’s Investigational Zilovertamab Vedotin in Combination with R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients with Diffuse Large B-cell LymphomaDecember 8th, 2024
- FDA Approves Merck’s KEYTRUDA® (Pembrolizumab) plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)September 18th, 2024
- Join now to see all
